- News Home
6 March 2014 1:04 pm ,
Vol. 343 ,
Antiretroviral drugs can protect people from becoming infected by HIV. But so-called pre-exposure prophylaxis, or PrEP...
Two studies show that eating a diet low in protein and high in carbohydrates is linked to a longer, healthier life, and...
Considered an icon of conservation science, researchers at World Wildlife Fund (WWF) headquarters in Washington, D.C.,...
The new atlas, which shows the distribution of important trace metals and other substances, is the first product of...
Early in April, the first of a fleet of environmental monitoring satellites will lift off from Europe's spaceport in...
Since 2000, U.S. government health research agencies have spent almost $1 billion on an effort to churn out thousands...
Magdalena Koziol, a former postdoc at Yale University, was the victim of scientific sabotage. Now, she is suing the...
- 6 March 2014 1:04 pm , Vol. 343 , #6175
- About Us
Rotavirus Vaccine Gets FDA Nod
15 December 1997 8:00 pm
A vaccine against rotavirus, a highly contagious bug that causes life-threatening diarrhea in young children, was deemed safe and effective by a U.S. Food and Drug Administration (FDA) advisory panel on Friday. Rotavirus killed 873,000 children last year, largely in underdeveloped countries.
The vaccine was created and patented by virologist and physician Albert Kapikian and his colleagues at the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland. It has been tested successfully on 18,000 children in numerous clinical trials in the United States, Finland, and Venezuela. In the latest trial, reported in the October issue of the Journal of Pediatrics, the vaccine prevented 70% of severe diarrhea cases on American Indian reservations, where incidence rates are higher than in the general U.S. population. "Not only could the routine use of this vaccine save lives and prevent illness, but it could save about $80 million [a year] in direct costs," says Mathuram Santosham, director of the Johns Hopkins Center for American Indian and Alaskan Native Health.
If approved by the FDA, the vaccine will be marketed by Wyeth-Ayerst Laboratories in St. David, Pennsylvania, for U.S. distribution. The vaccine would be administered in three doses at 2, 4, and 6 months of age along with the oral polio vaccine. The company is seeking a recommendation that all children be vaccinated against rotavirus from the Advisory Committee for Immunization Practices at the U.S. Centers for Disease Control and Prevention, which sets the schedule of childhood immunizations.